Get the Stockscreener App
30.78
3.12%
0.93
After Hours:
30.78
Forte Biosciences Inc stock is traded at $30.78, with a volume of 235.14K.
It is up +3.12% in the last 24 hours and up +3.78% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$29.85
Open:
$29.74
24h Volume:
235.14K
Relative Volume:
1.27
Market Cap:
$385.58M
Revenue:
-
Net Income/Loss:
$-51.74M
P/E Ratio:
-6.926
EPS:
-4.4441
Net Cash Flow:
$-44.57M
1W Performance:
+6.84%
1M Performance:
+3.78%
6M Performance:
+186.06%
1Y Performance:
+179.82%
1-Day Range:
$27.88
$32.20
1-Week Range:
$26.50
$32.20
52-Week Range:
$4.90
$35.62
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
30.78 | 373.93M | 0 | -51.74M | -44.57M | -4.4441 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Layoff Watch: Is Forte Biosciences Inc being accumulated by smart moneyJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - marketscreener.com
Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan
Forte Biosciences Insider Ups Holding By 30% During Year - simplywall.st
Aug Outlook: Will BEAM stock recover after earningsWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
(FBRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Dow Update: Will Forte Biosciences Inc announce a stock splitWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Expands By 55.5% - MarketBeat
Federated Hermes Inc. Acquires 563,147 Shares of Forte Biosciences, Inc. $FBRX - MarketBeat
Celiac Disease Pipeline 2025: FDA Updates, Therapy - openPR.com
(FBRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Celiac Disease Clinical Trial Pipeline Gains Momentum: 25+ - openPR.com
Trend Recap: Can META stock outperform in a bear marketTrade Volume Summary & AI Forecast Swing Trade Picks - baoquankhu1.vn
US Market Recap: What is the earnings history of Jupiter Neurosciences Inc2025 Stock Rankings & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
CD122’s double whammy makes for intriguing target - BioWorld MedTech
Is Forte Biosciences Inc. stock oversold or undervaluedJuly 2025 Sector Moves & Real-Time Volume Triggers - Bollywood Helpline
Is Forte Biosciences Inc a top pick in the sectorWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
Support Test: How does INVE compare to its peersQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
Layoff Watch: Is ERAS stock undervalued right nowMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Value Recap: Does Forte Biosciences Inc have pricing powerPortfolio Gains Report & Daily Growth Stock Tips - baoquankhu1.vn
Trade Recap: Is Forte Biosciences Inc. stock a hidden gemWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Up 267.7% in December - MarketBeat
Delaware court rules in D&O dispute - businessinsurance.com
Delaware court expands D&O insurer liability through meaningful linkage ruling - Insurance Business
A activityJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - ulpravda.ru
Will Forte Biosciences Inc. stock outperform international peersLayoff News & High Return Stock Watch Alerts - Улправда
Biopharma Co. Secures D&O Coverage For Shareholder Suit - Law360
Why Forte Biosciences Inc. stock is rated strong buyWeekly Investment Summary & Expert Curated Trade Ideas - Улправда
Will Forte Biosciences Inc. stock reach all time highs in 2025CPI Data & Expert Curated Trade Setups - Улправда
How supply shortages influence HCI stockJuly 2025 Review & Community Driven Trade Alerts - Улправда
What margin trends mean for VNET Group Inc. Depositary Receipt stockTrade Risk Report & Long-Term Safe Investment Ideas - Улправда
What valuation multiples suggest for HAYW stockWeekly Risk Summary & Consistent Growth Equity Picks - Улправда
ulpravda ru > 2026> What insider trading reveals about COLL stockChart Signals & Low Drawdown Momentum Ideas - ulpravda.ru
Will Quad Graphics Inc. stock return to pre crisis levels2025 Key Highlights & Expert Approved Trade Ideas - ulpravda.ru
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
(FBRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Will Avax Apparels and Ornaments Limited Bounce From 52 Week LowPortfolio Risk Assessment & Interactive Learning for Better Returns - earlytimes.in
Will Sahasra Electronic Solutions Limited Recover After Recent DeclineSupport and Resistance Levels & Access Free Risk Analysis Before You Invest - earlytimes.in
What drives Forte Biosciences Inc stock priceMean Reversion Trades & Receive Monthly Expert Trading Blueprints - earlytimes.in
TD Cowen Initiates Coverage of Forte Biosciences (FBRX) with Buy Recommendation - MSN
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock - Yahoo Finance
Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses - simplywall.st
Insider Buying: Antony Riley Acquires Shares of Forte Biosciences Inc (FBRX) - GuruFocus
Trading Bots Trigger Alerts on Shri Venkatesh Refineries Limited ActivityHigh Frequency Trading Trends & Fast Profit Trading Ideas - bollywoodhelpline.com
Indo Tech Transformers Limited (INDOTECH) Stock RalliesStock Liquidity Analysis & Discover Stocks Experts Are Watching - bollywoodhelpline.com
Dr. Lal PathLabs Limited (LALPATHLAB) Expands into New MarketRisk-Reward Ratio Analysis & Fast Profit Capital Growth - bollywoodhelpline.com
Forte Biosciences Inc. (FBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Shorts Report: Will Forte Biosciences Inc stock return to pre crisis levelsJuly 2025 Update & Consistent Profit Trade Alerts - moha.gov.vn
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):